Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.

VanDevanter DR, Heltshe SL, Spahr J, Beckett VV, Daines CL, Dasenbrook EC, Gibson RL, Raksha J, Sanders DB, Goss CH, Flume PA; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):607-615. doi: 10.1016/j.jcf.2017.04.004. Epub 2017 Apr 21.

2.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.

West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA; STOP investigators.

J Cyst Fibros. 2017 Sep;16(5):600-606. doi: 10.1016/j.jcf.2017.04.003. Epub 2017 Apr 29.

3.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):592-599. doi: 10.1016/j.jcf.2017.04.005. Epub 2017 Apr 29.

4.

Antibiotic duration and changes in FEV1 are not associated with time until next exacerbation in adult cystic fibrosis: a single center study.

Espel JC, Palac HL, Cullina JF, Clarke AP, McColley SA, Prickett MH, Jain M.

BMC Pulm Med. 2017 Nov 29;17(1):160. doi: 10.1186/s12890-017-0503-6.

5.

Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.

Heltshe SL, West NE, VanDevanter DR, Sanders DB, Beckett VV, Flume PA, Goss CH; STOP Study Group.

Contemp Clin Trials. 2018 Jan;64:35-40. doi: 10.1016/j.cct.2017.11.012. Epub 2017 Nov 21.

6.

Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.

Lechtzin N, West N, Allgood S, Wilhelm E, Khan U, Mayer-Hamblett N, Aitken ML, Ramsey BW, Boyle MP, Mogayzel PJ Jr, Goss CH.

Contemp Clin Trials. 2013 Nov;36(2):460-9. doi: 10.1016/j.cct.2013.09.004. Epub 2013 Sep 19.

7.

Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.

Heltshe SL, Goss CH, Thompson V, Sagel SD, Sanders DB, Marshall BC, Flume PA.

Thorax. 2016 Mar;71(3):223-9. doi: 10.1136/thoraxjnl-2014-206750. Epub 2015 Apr 24.

8.

Early detection of pulmonary exacerbations in children with Cystic Fibrosis by electronic home monitoring of symptoms and lung function.

van Horck M, Winkens B, Wesseling G, van Vliet D, van de Kant K, Vaassen S, de Winter-de Groot K, de Vreede I, Jöbsis Q, Dompeling E.

Sci Rep. 2017 Sep 27;7(1):12350. doi: 10.1038/s41598-017-10945-3. Erratum in: Sci Rep. 2018 Dec 13;8(1):17946.

9.

Rhinovirus-associated pulmonary exacerbations show a lack of FEV1 improvement in children with cystic fibrosis.

Cousin M, Molinari N, Foulongne V, Caimmi D, Vachier I, Abely M, Chiron R.

Influenza Other Respir Viruses. 2016 Mar;10(2):109-12. doi: 10.1111/irv.12353. Epub 2016 Jan 29.

10.

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.

Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE, Elborn JS.

J Cyst Fibros. 2016 Jul;15(4):495-502. doi: 10.1016/j.jcf.2015.12.004. Epub 2016 Feb 4.

11.

IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.

VanDevanter DR, Morris NJ, Konstan MW.

J Cyst Fibros. 2016 May;15(3):372-9. doi: 10.1016/j.jcf.2015.10.006. Epub 2015 Oct 23.

12.

Lung clearance index to monitor treatment response in pulmonary exacerbations in preschool children with cystic fibrosis.

Rayment JH, Stanojevic S, Davis SD, Retsch-Bogart G, Ratjen F.

Thorax. 2018 May;73(5):451-458. doi: 10.1136/thoraxjnl-2017-210979. Epub 2018 Feb 15.

PMID:
29449440
13.

Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis.

Sequeiros IM, Jarad N.

Chron Respir Dis. 2012 Feb;9(1):9-16. doi: 10.1177/1479972311433575.

PMID:
22308550
14.

Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS).

Gold LS, Patrick DL, Hansen RN, Goss CH, Kessler L.

J Cyst Fibros. 2019 May 21. pii: S1569-1993(19)30113-4. doi: 10.1016/j.jcf.2019.05.009. [Epub ahead of print]

PMID:
31126901
15.

Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

Wagener JS, Rasouliyan L, VanDevanter DR, Pasta DJ, Regelmann WE, Morgan WJ, Konstan MW; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Pediatr Pulmonol. 2013 Jul;48(7):666-73. doi: 10.1002/ppul.22652. Epub 2012 Aug 8.

16.

Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.

Elborn JS, Vataire AL, Fukushima A, Aballea S, Khemiri A, Moore C, Medic G, Hemels ME.

Clin Ther. 2016 Oct;38(10):2204-2226. doi: 10.1016/j.clinthera.2016.08.014. Epub 2016 Sep 29. Review.

17.

Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations.

VanDevanter DR, O'Riordan MA, Blumer JL, Konstan MW.

Respir Res. 2010 Oct 6;11:137. doi: 10.1186/1465-9921-11-137.

18.

Defining a pulmonary exacerbation in cystic fibrosis.

Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B.

J Pediatr. 2001 Sep;139(3):359-65.

PMID:
11562614
19.

Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.

Hoppe JE, Wagner BD, Sagel SD, Accurso FJ, Zemanick ET.

BMC Pulm Med. 2017 Dec 11;17(1):188. doi: 10.1186/s12890-017-0546-8.

20.

Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.

Sanders DB, Zhao Q, Li Z, Farrell PM.

Pediatr Pulmonol. 2017 Oct;52(10):1268-1275. doi: 10.1002/ppul.23765. Epub 2017 Sep 7.

Supplemental Content

Support Center